Home/Filings/4/0001104659-14-061090
4//SEC Filing

T2 Biosystems, Inc. 4

Accession 0001104659-14-061090

CIK 0001492674operating

Filed

Aug 13, 8:00 PM ET

Accepted

Aug 14, 4:34 PM ET

Size

19.7 KB

Accession

0001104659-14-061090

Insider Transaction Report

Form 4
Period: 2014-08-12
Transactions
  • Purchase

    Common Stock

    2014-08-12$11.00/sh+454,545$4,999,9952,523,300 total(indirect: See footnote)
  • Conversion

    Common Stock

    2014-08-12+2,068,7552,068,755 total(indirect: See footnote)
  • Conversion

    Series E Convertible Preferred Stock

    2014-08-12549,8510 total(indirect: See footnote)
    Exercise: $0.00Common Stock (323,441 underlying)
  • Conversion

    Series D Convertible Preferred Stock

    2014-08-122,967,0330 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,745,313 underlying)
Transactions
  • Conversion

    Common Stock

    2014-08-12+2,068,7552,068,755 total(indirect: See footnote)
  • Purchase

    Common Stock

    2014-08-12$11.00/sh+454,545$4,999,9952,523,300 total(indirect: See footnote)
  • Conversion

    Series D Convertible Preferred Stock

    2014-08-122,967,0330 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,745,313 underlying)
  • Conversion

    Series E Convertible Preferred Stock

    2014-08-12549,8510 total(indirect: See footnote)
    Exercise: $0.00Common Stock (323,441 underlying)
Transactions
  • Conversion

    Common Stock

    2014-08-12+2,068,7552,068,755 total(indirect: See footnote)
  • Conversion

    Series D Convertible Preferred Stock

    2014-08-122,967,0330 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,745,313 underlying)
  • Purchase

    Common Stock

    2014-08-12$11.00/sh+454,545$4,999,9952,523,300 total(indirect: See footnote)
  • Conversion

    Series E Convertible Preferred Stock

    2014-08-12549,8510 total(indirect: See footnote)
    Exercise: $0.00Common Stock (323,441 underlying)
ELMS STEVE
10% Owner
Transactions
  • Conversion

    Common Stock

    2014-08-12+2,068,7552,068,755 total(indirect: See footnote)
  • Purchase

    Common Stock

    2014-08-12$11.00/sh+454,545$4,999,9952,523,300 total(indirect: See footnote)
  • Conversion

    Series D Convertible Preferred Stock

    2014-08-122,967,0330 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,745,313 underlying)
  • Conversion

    Series E Convertible Preferred Stock

    2014-08-12549,8510 total(indirect: See footnote)
    Exercise: $0.00Common Stock (323,441 underlying)
Transactions
  • Conversion

    Common Stock

    2014-08-12+2,068,7552,068,755 total(indirect: See footnote)
  • Purchase

    Common Stock

    2014-08-12$11.00/sh+454,545$4,999,9952,523,300 total(indirect: See footnote)
  • Conversion

    Series D Convertible Preferred Stock

    2014-08-122,967,0330 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,745,313 underlying)
  • Conversion

    Series E Convertible Preferred Stock

    2014-08-12549,8510 total(indirect: See footnote)
    Exercise: $0.00Common Stock (323,441 underlying)
Transactions
  • Conversion

    Common Stock

    2014-08-12+2,068,7552,068,755 total(indirect: See footnote)
  • Conversion

    Series E Convertible Preferred Stock

    2014-08-12549,8510 total(indirect: See footnote)
    Exercise: $0.00Common Stock (323,441 underlying)
  • Purchase

    Common Stock

    2014-08-12$11.00/sh+454,545$4,999,9952,523,300 total(indirect: See footnote)
  • Conversion

    Series D Convertible Preferred Stock

    2014-08-122,967,0330 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,745,313 underlying)
Footnotes (2)
  • [F1]The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
  • [F2]The reportable securities are owned directly by Aisling Capital III, LP ("Aisling"), and held indirectly by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.

Documents

1 file

Issuer

T2 Biosystems, Inc.

CIK 0001492674

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001492674

Filing Metadata

Form type
4
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 4:34 PM ET
Size
19.7 KB